Diagnostics News and Research

RSS

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee.

5 Mar 2010

Quest Diagnostics, Surescripts announce agreement to pioneer integrated service to improve clinical outcomes

Two of the nation's largest healthcare information networks, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Surescripts®, The Nation's E-Prescription Network™, today announced an agreement to pioneer the formation of an integrated service to make laboratory and prescription information broadly and easily accessible to physicians.

From Quest Diagnostics 5 Mar 2010

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

According to estimates from the American Cancer Society, melanoma, the most serious form of skin cancer, was responsible for an estimated 8,650 deaths in the United States in 2009. Of growing concern among dermatologists is the fact that melanoma is now the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old.

5 Mar 2010

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.

5 Mar 2010

Diamedix and Delta Biologicals’ suite of diagnostic tests: Fumouze Diagnostics to be exclusive distributor in France

IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.’s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics’ subsidiary located in Italy. The initial term of the distribution agreement is three years.

5 Mar 2010

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

Betty King reported to her new position as U.S. ambassador to the U.N. in Geneva on Wednesday, the Associated Press reports. "Washington's Geneva mission had been without an ambassador since Warren W. Tichenor left his post on Jan. 20, 2009 - when Barack Obama was sworn in as president," according to the news service (3/3).

4 Mar 2010

BioMS Medical invests in Spectral Diagnostics securities

BioMS Medical Corp. acquired pursuant to a private placement of units, beneficial ownership and control over 30,000,000 common shares and 15,000,000 common shares purchase warrants of Spectral Diagnostics Inc..

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

3 Mar 2010

ASPEX to display game-changing PSEM eXpress analyzer at Pittcon 2010

ASPEX Corporation has been advancing the novel Personal Scanning Electron Microscope (PSEM) platform since its first product generation was released in 1992. Since then, it has been "shifting" where SEMs are traditionally installed, "shifting" when SEMs are utilized in industrial processes, and fundamentally "shifting" how SEMs are identified. Come experience the shift at Pittcon 2010, in Orlando, FL from March 1-4.

3 Mar 2010

Biomagnetics Diagnostics announces accelerated delivery timetable for integrated optical biosensor

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced its accelerated timetable for delivery of the world's first handheld, integrated optical biosensor.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Cleveland HeartLab completes $3.0M fundraising round

Cleveland HeartLab LLC (CHL) today announced that it has completed a $3.0-million fundraising round. The company’s new shareholders include local business leaders, and Glengary LLC, Second Generation Ltd. and Zapis Capital Group LLC.

2 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

Diagnostics News and Research

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

Quest Diagnostics, Surescripts announce agreement to pioneer integrated service to improve clinical outcomes

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

Diamedix and Delta Biologicals’ suite of diagnostic tests: Fumouze Diagnostics to be exclusive distributor in France

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

Enigma Diagnostics opens new Regional HQ office in San Diego

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

BioMS Medical invests in Spectral Diagnostics securities

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

ASPEX to display game-changing PSEM eXpress analyzer at Pittcon 2010

Biomagnetics Diagnostics announces accelerated delivery timetable for integrated optical biosensor

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Cleveland HeartLab completes $3.0M fundraising round

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Sanquin Blood Supply Foundation, Netherlands Vaccine Institute launch AmpVacs project to develop influenza A vaccine

Study results of new PCR technology that reports mutations associated with FXS announced

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News